Bristol-Myers Squibb (BMY) stock has experienced a series of significant events recently. The stock has seen a fall,
prompting investor attention on future activity. It has been under spotlight questioning if it should be considered for
buy, sell, or hold in 2026. A notable development includes the
new investment by Financiere des Professionnels Fonds d investissement inc. in BMY. The company has also seen active trading with unusually high options volumes.
Notable
buying and selling activities from various asset management firms including Ascent Group LLC, Diversified Trust Co, Fort Washington Investment Advisors Inc. OH, 3Chopt, Allspring Global Investments Holdings LLC, and Avaii Wealth Management LLC have been reported. BMY's stock resilience was compared to AMGN, offering insights into biotech market stability.
Regulatory approval by the FDA for Breyanzi as the first CAR T therapy for marginal zone lymphoma is a major scientific triumph for the company. Amid all the actions,
multiple upgrades and positive ratings from renowned institutions namely BofA, Jefferies, and Goldman Sachs, and a bullish sentiment from analysts have played a vital role in maintaining spotlight on BMY.
In spite of the recent fluctuations, BMY still appears undervalued according to some analysts. The recent dividend hike by BMY and its growth pipeline are the key attractions for those looking for a
high-yield dividend.
Bristol-Myers Squibb BMY News Analytics from Tue, 16 Sep 2025 07:00:00 GMT to Sat, 03 Jan 2026 22:56:51 GMT -
Rating 7
- Innovation 6
- Information 7
- Rumor 0
